Markus Kroenke
Overview
Explore the profile of Markus Kroenke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, et al.
J Nucl Med
. 2023 May;
64(7):1036-1042.
PMID: 37230531
Our objective was to compare the ability to detect histopathologically confirmed lymph node metastases by early and delayed [Tc]Tc-PSMA-I&S SPECT/CT in early biochemically recurrent prostate cancer. We retrospectively analyzed 222...
2.
Kroenke M, Schweiger L, Horn T, Haller B, Schwamborn K, Wurzer A, et al.
J Nucl Med
. 2022 Apr;
63(12):1809-1814.
PMID: 35393348
F-rhPSMA-7, and its single diastereoisomer form, F-rhPSMA-7.3, are prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals. Here, we investigated their accuracy for the assessment of lymph node (LN) metastases validated by histopathology. Data...
3.
Ilhan H, Kroenke M, Wurzer A, Unterrainer M, Heck M, Belka C, et al.
J Nucl Med
. 2022 Mar;
63(8):1208-1214.
PMID: 35273094
This bicentric, retrospective analysis investigated the efficacy of PET/CT with a novel theranostic prostate-specific membrane antigen (PSMA)--targeting ligand, F-rhPSMA-7, in patients with biochemical recurrence (BCR) of prostate cancer after curative-intent...
4.
Langbein T, Wang H, Rauscher I, Kroenke M, Knorr K, Wurzer A, et al.
J Nucl Med
. 2022 Jan;
63(9):1334-1342.
PMID: 34992154
F-rhPSMA-7.3, the lead compound of a new class of radiohybrid prostate-specific membrane antigen (rhPSMA) ligand, is currently in phase III trials for prostate cancer (PCa) imaging. Here, we describe our...
5.
Kroenke M, Mirzoyan L, Horn T, Peeken J, Wurzer A, Wester H, et al.
J Nucl Med
. 2020 Dec;
62(8):1082-1088.
PMID: 33277394
Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands are a new class of prostate cancer theranostic agents. F-rhPSMA-7 offers the advantages of F labeling and low urinary excretion compared with Ga-PSMA-11. Here,...
6.
Peeken J, Shouman M, Kroenke M, Rauscher I, Maurer T, Gschwend J, et al.
Eur J Nucl Med Mol Imaging
. 2020 May;
47(13):2968-2977.
PMID: 32468251
Purpose: In recurrent prostate carcinoma, determination of the site of recurrence is crucial to guide personalized therapy. In contrast to prostate-specific membrane antigen (PSMA)-positron emission tomography (PET) imaging, computed tomography...
7.
Eiber M, Kroenke M, Wurzer A, Ulbrich L, Jooss L, Maurer T, et al.
J Nucl Med
. 2019 Dec;
61(5):696-701.
PMID: 31836682
F-labeled prostate-specific membrane antigen (PSMA) PET tracers are increasingly used in preference to Ga-PSMA-11 for restaging biochemical recurrence (BCR) of prostate cancer. They are associated with longer half-lives, larger-scale production,...
8.
Kroenke M, Wurzer A, Schwamborn K, Ulbrich L, Jooss L, Maurer T, et al.
J Nucl Med
. 2019 Dec;
61(5):710-715.
PMID: 31836681
F-rhPSMA-7 (radiohybrid prostate-specific membrane antigen [PSMA]) is a novel ligand for PET imaging. Here, we present data from a retrospective analysis using PET/CT and PET/MRI examinations to investigate the efficacy...
9.
Kroenke M, Hirata K, Gafita A, Watanabe S, Okamoto S, Magota K, et al.
PLoS One
. 2019 Mar;
14(2):e0213111.
PMID: 30818360
Background: Hypoxia can induce radiation resistance and is an independent prognostic marker for outcome in head and neck cancer. As 18F-FMISO (FMISO), a hypoxia tracer for PET, is far less...
10.
Furuya S, Manabe O, Nanbu T, Yamashita N, Shinnno Y, Kasai K, et al.
Intern Med
. 2017 Dec;
57(8):1131-1134.
PMID: 29279490
We herein report a rare case of mucinous tubular and spindle cell carcinoma (MTSCC) in an 80-year-old woman. A well circumscribed tumor located on the right kidney was discovered incidentally...